Theranos reaches settlement with Partner Fund Management. Tender offer recapitalizing major shareholders scheduled to close May 15.
Company to reimburse more than those whose tests were voided and corrected; Resolution ends all existing and potential claims against Theranos in the state.
CMS withdraws revocation of CLIA certificates and reduces civil monetary penalty; Theranos withdraws appeal, completing exit from the clinical lab business.
Theranos, Inc. announced that engineering and biomedical device design experts have joined the company’s newly created Technology Advisory Board (TAB).
The Wall Street Journal reports on Theranos and the company's AACC presentation on August 1st.